Please select the eligibility criteria that correspond to the clinical trial below.
Title: Management of Superficial Thrombophlebitis
Brief Summary: The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).


Options:
A: Inclusion Criteria:

* all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography.

Exclusion Criteria:

* patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible
B: Inclusion Criteria:

* Patients with confirmed upper or lower extremity superficial thrombophlebitis by ultrasound imaging

Exclusion Criteria:

* Active, clinically significant bleeding
* Known hypersensitivity to NSAIDS, heparin or derivatives
* Currently pregnant or \< 1 week post-partum
* Acquired bleeding diathesis
* Known inherited bleeding disorder
* Renal failure
* Extremes of weight
* unable to return for repeat diagnostic testing or follow-up visit
* Concurrent deep-vein thrombosis
C: Inclusion Criteria:

* acute symptomatic supragenual superficial vein thrombosis of the leg
* at least one of the following major risk factor for VTE:
* age \> 65 years or
* male sex or
* history of DVT/PE/SVT or
* history of cancer or active cancer or
* autoimmune disease or
* SVT of a non-varicose vein
* thrombus extension of at least 5 cm
* proximal thrombus end with more than 3 cm distance to the saphenofemoral junction (SFJ)
* age \> 18 years
* written informed consent

Exclusion Criteria:

* other indication for therapeutic anticoagulation such as acute deep vein thrombosis, acute pulmonary embolism, atrial fibrillation with indication for anticoagulant therapy
* any PE or DVT within last 6 months before inclusion
* clinical signs of PE without objective exclusion (CT or VQ scan, angiography)
* SVT without signs of thrombotic/inflammatory activity (activity signs: diameter \> 4 mm, pain, redness, elevated local or systemic temperature)
* SVT after sclerotherapy
* Duration of symptoms \> 3 weeks
* pretreatment of more than 72 h with therapeutic dosages of oral or parenteral anticoagulants
* pretreatment of more than 5 days with subtherapeutic oral or parenteral anticoagulants
* indication for escalated antiplatelet therapy (monotherapy with aspirin \> 325 g/d and any dual antiplatelet therapy)
* SVT closer than 3 cm to saphenofemoral junction (SVJ)
* anticipated superficial vein surgery within 90 days
* anticipated thrombolytic therapy within 90 days
* manifest clinically relevant bleeding
* clinically relevant bleeding in the last 30 days before study inclusion
* major surgery within last 30 days before inclusion
* ophthalmic, spinal or cerebral surgery within last 90 days
* severe head trauma within last 90 days
* hemorrhagic stroke within last 12 months
* hereditary or acquired severe hemorrhagic diathesis
* gastrointestinal bleeding within last 90 days requiring endoscopy
* uncontrolled arterial hypertension (systolic \> 180 mm Hg, diastolic \> 110 mm Hg)
* acute endocarditis
* low platelet count (\< 100 x 109/l)
* Prothrombin time \< 50 %
* calculated creatinine clearance \< 30 ml/min
* significant liver disease such as acute hepatitis, chronic active hepatitis, cirrhosis
* life expectancy \< 3 months
* any contraindications listed for rivaroxaban or fondaparinux
* women of child bearing potential without safe contraception method
* pregnant or breastfeeding women
* participation in another trial with pharmacological intervention
D: Inclusion Criteria:

* written informed consent to participate in the study
* symptomatic thrombophlebitis of the great saphenous vein measuring at least 10 cm or the small saphenous vein measuring at least 10 cm or a collateral of the great saphenous vein measuring at least 10 cm (within 7 days from the onset of the disease)
* age 18 to 85 years
* body weight 65 to 85 kg

Exclusion Criteria:

* inability to objectively confirm the diagnosis
* excessive or insufficient body weight (more than 85 kg or less than 60 kg)
* history of previous thromboembolic complications (including previous thrombophlebitis, vein thrombosis and pulmonary embolism)
* contraindications for anticoagulant treatment
* active bleeding or high risk for bleeding contraindicating treatment with (LMWH)
* diseases requiring anticoagulant treatment
* proximal or distal deep vein thrombosis or pulmonary embolism (either symptomatic or incidentally found asymptomatic)
* thrombophlebitis of the great saphenous vein at a distance of less than 5 cm from the saphenofemoral junction or thrombophlebitis of small saphenous vein at a distance of less than 3 cm from the saphenopopliteal junction
* thrombophlebitis that might arise as a consequence of a previous intravenous access (infusion thrombophlebitis), sclerotherapy or surgical treatment of chronic vein insufficiency
* pregnancy, known malignant disease or chemotherapy
* immobility
* advanced stage of kidney failure (GF \< 30 mL/min/1.72 m2)
* significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (ALT) \>\\= 2 times the upper limit of normal (ULN), or total bilirubin (TBL) x 1.5 times the ULN

Answer: B